These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21792865)

  • 1. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
    Feldman DR; Patil S; Trinos MJ; Carousso M; Ginsberg MS; Sheinfeld J; Bajorin DF; Bosl GJ; Motzer RJ
    Cancer; 2012 Feb; 118(4):981-6. PubMed ID: 21792865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
    Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC
    J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
    Oechsle K; Honecker F; Cheng T; Mayer F; Czaykowski P; Winquist E; Wood L; Fenner M; Glaesener S; Hartmann JT; Chi K; Bokemeyer C; Kollmannsberger C
    Ann Oncol; 2011 Dec; 22(12):2654-2660. PubMed ID: 21415240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.
    Oing C; Hentrich M; Lorch A; Gläser D; Rumpold H; Ochsenreither S; Richter S; Dieing A; Zschäbitz S; Pereira RR; Bokemeyer C; Seidel C
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):449-455. PubMed ID: 31838576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
    Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Turkula S; Ginsberg MS; Ishill N; Patil S; Carousso M; Bosl GJ; Motzer RJ
    Invest New Drugs; 2010 Aug; 28(4):523-8. PubMed ID: 19547919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
    Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
    Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
    Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
    Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Einhorn LH; Quinn DI; Loriot Y; Joffe JK; Vaughn DJ; Fléchon A; Hajdenberg J; Halim AB; Zahir H; Motzer RJ
    Invest New Drugs; 2013 Aug; 31(4):1016-22. PubMed ID: 23417696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
    Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
    BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
    Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
    Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
    Lorch A; Kleinhans A; Kramar A; Kollmannsberger CK; Hartmann JT; Bokemeyer C; Rick O; Beyer J
    J Clin Oncol; 2012 Mar; 30(8):800-5. PubMed ID: 22291076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
    Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
    Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
    Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.